Dossier assessment

Benralizumab (eosinophilic granulomatosis with polyangiitis) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis

Result of dossier assessment:

Patients with organ-threatening or life-threatening manifestations: added benefit not proven
Patients without organ-threatening or life-threatening manifestations: added benefit not proven

2025-05-15 A G-BA decision was published.

Project no.: A24-113
Commission: Commission awarded on 25.11.2024 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Immune system and infections
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A24-113_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.